Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 24, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - April 24, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/24/14 - Alexion CEO Received $30M in Compensation in 2013 [The Hartford Courant :: ]
April 24 The CEO of Alexion, the Cheshire- based pharmaceutical company that makes the most expensive drug in the world, received $30.15 million in compensation last year, according to a federal filing Wednesday. Leonard Bell's Yale research, only has one product so far: Soliris. The drug treats ultra-rare diseases and generally insurers pay more
4/24/14 - Axiom Food's Oryzatein Becomes First Rice Protein Ever To Earn GRAS Approval
By a News Reporter-Staff News Editor at Politics& Government Week On the heels of a 2013 double-blind clinical trial which proved Axiom Food's Oryzatein plant-based brown rice protein equals animal-based whey in building and repairing muscles, Oryzatein has now become the very first brown rice protein to be granted GRAS approval. The GRAS appr
4/24/14 - Baxter Announces FDA Approval of ADVATE (Antihemophilic Factor [Recombinant]) with BAXJECT III Reconstitution System
DEERFIELD, Ill.- Baxter International Inc. today announced that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE. "ADVATE has the widest range of dosage formulations, allowing for more precise customized dosing, and with the ADVATE with BAXJECT III reconstitution system, patients can prepare their treatment
4/24/14 - BRIEF: Coral Gables drug company to make new medicine available at no cost [The Miami Herald :: ]
April 23 Coral Gables- based Catalyst Pharmaceutical Partners soon will make its investigational drug Firdapse available at no cost to patients with a certain autoimmune disorder. Catalyst said it expects to submit an application for Firdapse's approval with the U.S. Food and Drug Administration next year. Catalyst has been leading the developmen
4/24/14 - Canada : Proskauer Expands Life Sciences Practice with Noted Patent Litigator Siegmund Gutman in Los Angeles [TendersInfo (India)]
Mr. Gutman is an accomplished patent litigator, having frequently represented clients before trial and appellate courts, as well as arbitration panels. In the life sciences area, Mr. Gutman concentrates his practice on developing and executing market exclusivity and freedom-to-operate strategies, including patent office and FDA regulatory strategie
4/24/14 - Centrose Assigned Patent
ALEXANDRIA, Va., April 24 Centrose, Madison, Wis., has been assigned a patent developed by Charles R. Hutchinson, Madison, Wis., Mohammed S. Shekhani, Madison, Wis., and James R. Prudent, Madison, Wis., for "glycoside compounds and pharmaceutical compositions thereof." The patent application was filed on Dec. 27, 2012. Written by Amal Ahmed; edit
4/24/14 - Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Disease
Cynapsus Therapeutics Inc., a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot study of a single 25 mg sublingual strip dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug in the United States,..
4/24/14 - Cynapsus Therapeutics Inc. : Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Disease
April 24, 2014 TORONTO, CANADA- Cynapsus Therapeutics Inc., a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot study of a single 25 mg sublingual strip dose of apomorphine. APL-130277 is an easy-to- administer, fast-acting reformulation of apomorphine, which is the only appr
4/24/14 - Data from Upsher-Smith's Epilepsy Portfolio to be Presented at Meeting of the American Academy Of Neurology [Health & Beauty Close - Up]
Upsher-Smith Laboratories, Inc.. a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, will highlight new pooled phase 1 data from studies in healthy adults comparing the adverse event profile of USL255 with immediate-release topiramate in a poster presentation at the 66
4/24/14 - FDA Accepts Gilead Sciences' Drug Applications for Cobicistat and Elvitegravir for HIV Therapy [Health & Beauty Close - Up]
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has accepted the company's refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elviteg
4/24/14 - FDA approves Sylvant for rare Castleman's disease
Release date- 23042014- The U.S. Food and Drug Administration today approved Sylvant to treat patients with multicentric Castleman's disease, a rare disorder similar to lymphoma. 'Sylvant is the first FDA- approved drug to treat patients with MCD,' said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Ce
4/24/14 - HPV: Do Vaccinated Women Still Need a Pap Smear? polyDNA Answers Survey Question and Recommends Novirin Against the Latent HPV
polyDNA's latest survey discovered that 72% of female respondents who had been vaccinated against the human papillomavirus, wanted to know if they still need to have a regular pap smear. "Already got immunized with the HPV vaccine? The formula of this natural antiviral product was shown to reduce HPV symptoms in a post-marketing clinical study tha
4/24/14 - New breast cancer results illustrate promise and potential of I-SPY 2 trial
By a News Reporter-Staff News Editor at Women's Health Weekly In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer. The phase 2 data was presented in San Diego at the annual meeti
4/24/14 - Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale, Pharmaceuticals, Eye Care and Generics
Release date- 23042014- Basel- Novartis announced today that it has reached a definitive agreement with GlaxoSmithKline plc to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK...
4/24/14 - Novartis Benefits a Bit More from Glaxo Partnership: Kalorama
Healthcare market research firm Kalorama Information says the pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline.. The two drug makers will cooperate and among other transactions, Glaxo will buy Novartis's vaccine business and Novartis will gain Glaxo's oncology drug pipeline.
4/24/14 - Patent Application Titled "Pharmaceutical Formulation Comprising an Antibody against P-Selectin and a Sugar Selected from Sucrose and Trehalose"...
Patent Application Titled "Pharmaceutical Formulation Comprising an Antibody against P-Selectin and a Sugar Selected from Sucrose and Trehalose" Published Online. By a News Reporter-Staff News Editor at Politics& Government Week According to news reporting originating from Washington, D.C., by VerticalNews journalists, a patent application by the
4/24/14 - Pharmacyclics to Present Phase III and Long Term Follow Up Data on Imbruvica in Chronic Lymphocytic Leukemia (CLL) at ASCO [Health & Beauty Close - Up]
Pharmacyclics, Inc. announced that data from the Phase III PCYC- 1112 study of single agent Imbruvica vs. ofatumumab, an established therapy in relapsed refractory CLL, as well as data from an Independent Efficacy Evaluation of Imbruvica after three years of follow-up, will be presented at the American Society of Clinical Oncology 50th Annual Meeti
4/24/14 - Researchers Submit Patent Application, "Systems and Processes for Tracking Items", for Approval
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventor Pizzuto, Thomas J., filed on September 23, 2013, was made available online on April 10, 2014. No assignee for this patent application has been made. In the case of pharmaceuticals, wher
4/24/14 - Risperdal Breast-Growth Lawyer Help: Resource4thePeople Encouraged by Consumer Response to No-Cost Reviews of Breast-Growth Claims
These non-approved uses of Risperdal were recently outlined* by the U.S. Justice Department and the Food and Drug Administration in the resolution of charges involving multimillion dollar criminal and civil penalties. The Justice Department and FDA issued a joint Nov. 4, 2013 press release* in which they explained the resolution of charges against.
4/24/14 - Tersus Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., April 24 Tersus Pharmaceuticals, Mentor, Ohio, has been assigned a patent developed by Jeffrey Green, University Heights, Ohio, for "compositions and methods comprising C16: 1 n7-palmitoleate." The patent application was filed on March 2, 2012. Written by Kusum Sangma; edited by Jaya Anand.
4/24/14 - Wisconsin Alumni Research Foundation Assigned Patent
ALEXANDRIA, Va., April 24 Wisconsin Alumni Research Foundation, Madison, Wis., has been assigned a patent developed by Gabriela G. Cezar, Middleton, Wis., for "reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds and other chemicals." The patent application was filed on April 10, 2007. Written
4/24/14 - Zurex Pharma Assigned Patent
ALEXANDRIA, Va., April 24 Zurex Pharma, Middleton, Wis., has been assigned a patent developed by Stephen R. Ash, Lafayette, Ind., and Janusz Steczko, West Lafayette, Ind., for "antimicrobial compositions and methods of use." The patent application was filed on March 4, 2013. Written by Amal Ahmed; edited by Jaya Anand.
4/23/14 - "Non-Enteric Coated Pharmaceutical Composition and Use Thereof" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors LIN, Wen Jen; Alai, Milind, filed on September 28, 2012, was made available online on April 10, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to National Taiwan University.
4/23/14 - AbbVie to Present Data on Investigational Compounds at the 2014 American Society of Clinical Oncology Annual Meeting
AbbVie today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50 th Annual Meeting of the American Society of Clinical Oncology, May 30- June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative therapies that improve
4/23/14 - Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, presented interim data demonstrating dose dependent increases in hemoglobin in patients with...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415